X. Bai

发表

High expression of truncated GLI3 is associated with poor overall survival in patients with non-small cell lung cancer.

Yi-long Wu, Chongrui Xu, S. An, 2013, Cancer biomarkers : section A of Disease markers.

Pyrolysis behavior of coal in a moving bed with baffled internals under different residence times

Z. Qi, Xu Zhang, Yang Zhang, 2021, Journal of Fuel Chemistry and Technology.

Effects of interval between fusion and activation, cytochalasin B treatment, and number of transferred embryos, on cloning efficiency in goats.

Yong Zhang, F. Quan, Jun Liu, 2011, Theriogenology.

Lysophosphatidic acid suppresses apoptosis of high-grade serous ovarian cancer cells by inducing autophagy activity and promotes cell-cycle progression via EGFR-PI3K/Aurora-AThr288-geminin dual signaling pathways

P. Jia, Lifei Fan, Man Wu, 2022, Frontiers in Pharmacology.

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2017, Lung cancer.

Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines

Yi-long Wu, S. An, Xuchao Zhang, 2016, PloS one.

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations

Yi-long Wu, Xue-Ning Yang, W. Zhong, 2017, British Journal of Cancer.

Influence of IFN alpha-2b and BCG on the release of TNF and IL-1 by Kupffer cells in rats with hepatoma.

L. Cheng, X. Bai, Y. Gu, 2001, World journal of gastroenterology.

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2019, EBioMedicine.

Biomarker-integrated study of single agent targeting molecular alterations of PI3KCA, MET, ALK, ROS1, KRAS, NRAS or BRAF in advanced NSCLC: Phase 2 umbrella trial in China (CTONG1505).

Y. Wu, H-J. Chen, A. Myers, 2018, Annals of Oncology.

Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.

Yi-long Wu, Jin-Ji Yang, Jie Huang, 2021, Clinical lung cancer.

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, Oncotarget.

Epidermal growth factor receptor is associated with the onset of skeletal related events in non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, Shu-Mei Huang, 2017, Oncotarget.

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial

Yangqiu Li, Jin-Ji Yang, Chongrui Xu, 2023, Nature Network Boston.

The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge.

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2019, Science bulletin.

Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy

Jin-Ji Yang, W. Zhong, K. Yin, 2023, Molecular oncology.

Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2023, EClinicalMedicine.

Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC.

Jin-Ji Yang, Xue-Ning Yang, Xuchao Zhang, 2024, Cell reports.